BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11306447)

  • 1. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.
    Senekowitsch-Schmidtke R; Schuhmacher C; Becker KF; Nikula TK; Seidl C; Becker I; Miederer M; Apostolidis C; Adam C; Huber R; Kremmer E; Fischer K; Schwaiger M
    Cancer Res; 2001 Apr; 61(7):2804-8. PubMed ID: 11306447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
    Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
    Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel mutation-specific monoclonal E-cadherin antibodies make possible allele differentiation at the protein level in tumors].
    Becker I; Becker KF; Kremmer E; Eulitz M; Handschuh G; Höfler H
    Verh Dtsch Ges Pathol; 1999; 83():233-9. PubMed ID: 10714216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional allelic loss detected at the protein level in archival human tumours using allele-specific E-cadherin monoclonal antibodies.
    Becker KF; Kremmer E; Eulitz M; Schulz S; Mages J; Handschuh G; Wheelock MJ; Cleton-Jansen AM; Höfler H; Becker I
    J Pathol; 2002 Aug; 197(5):567-74. PubMed ID: 12210074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody.
    Becker KF; Kremmer E; Eulitz M; Becker I; Handschuh G; Schuhmacher C; Müller W; Gabbert HE; Ochiai A; Hirohashi S; Höfler H
    Am J Pathol; 1999 Dec; 155(6):1803-9. PubMed ID: 10595908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility.
    Handschuh G; Candidus S; Luber B; Reich U; Schott C; Oswald S; Becke H; Hutzler P; Birchmeier W; Höfler H; Becker KF
    Oncogene; 1999 Jul; 18(30):4301-12. PubMed ID: 10439038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi.
    Kennel SJ; Boll R; Stabin M; Schuller HM; Mirzadeh S
    Br J Cancer; 1999 Apr; 80(1-2):175-84. PubMed ID: 10389994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.
    Beck R; Seidl C; Pfost B; Morgenstern A; Bruchertseifer F; Baum H; Schwaiger M; Senekowitsch-Schmidtke R
    Cancer Sci; 2007 Aug; 98(8):1215-22. PubMed ID: 17561973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diffuse stomach carcinoma: from H&E diagnosis and molecular pathology to specific therapy].
    Höfler H
    Verh Dtsch Ges Pathol; 1999; 83():148-54. PubMed ID: 10714205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.
    Bremm A; Walch A; Fuchs M; Mages J; Duyster J; Keller G; Hermannstädter C; Becker KF; Rauser S; Langer R; von Weyhern CH; Höfler H; Luber B
    Cancer Res; 2008 Feb; 68(3):707-14. PubMed ID: 18245470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
    Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
    McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
    Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled antibody.
    Simonson RB; Ultee ME; Hauler JA; Alvarez VL
    Cancer Res; 1990 Feb; 50(3 Suppl):985s-988s. PubMed ID: 2297751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.